Understanding Why Generic Medical Appeals No Longer Work
As payers continue to intensify scrutiny of immunohistochemistry (IHC) utilization, pathology groups are seeing a corresponding increase in denials based on medical necessity and perceived overutilization. While these denials can be frustrating, they also present an opportunity to reevaluate appeal strategies and improve reimbursement outcomes.
A recent case study compiled by Lighthouse’s RCM Consulting Team highlighted an important lesson for pathology groups: not all Medical Unlikely Edits (MUEs) are created equal.
Complete the form below to access the PDF
Why Labs and Pathology Groups Should Reconsider Their Appeal Strategy
Medical Unlikely Edits (MUEs), developed under the National Correct Coding Initiative (NCCI), are utilized by Medicare and frequently adopted by commercial payers to identify potentially excessive units of service. Some MUEs represent absolute limits and generally cannot be exceeded under any circumstance. Others serve as utilization benchmarks that may be exceeded when supported by appropriate clinical documentation and medical necessity.
A well-crafted appeal that directly addresses payer concerns often has a significantly higher likelihood of success than a generic submission. While these appeals may require additional effort upfront, the investment frequently yields greater reimbursement recovery and reduces the likelihood of repeated denials.
Lighthouse Acquires MJB Lab Consulting, Expanding Medical Leadership Services